Page last updated: 2024-09-03

angiotensin ii, des-phe(8)- and deoxycytidine

angiotensin ii, des-phe(8)- has been researched along with deoxycytidine in 3 studies

Compound Research Comparison

Studies (angiotensin ii, des-phe(8)-)	Trials (angiotensin ii, des-phe(8)-)	Recent Studies (post-2010) (angiotensin ii, des-phe(8)-)	Studies (deoxycytidine)	Trials (deoxycytidine)	Recent Studies (post-2010) (deoxycytidine)
1,533	21	995	18,160	4,652	8,898

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cruickshank, S; Delmore, JE; diZerega, GS; Drummond, L; Peterson, KJ; Pham, H; Reed, E; Rodgers, KE; Schwartz, BM	1
diZerega, GS; Espinoza, TB; Meeks, CJ; Roda, N; Rodgers, KE	1
Gaffney, K; Louie, S; Rodgers, K; Soto, M; Weinberg, M	1

Trials

1 trial(s) available for angiotensin ii, des-phe(8)- and deoxycytidine

Article	Year
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia	2013

Article

Year

Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.

Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia

2013

Other Studies

2 other study(ies) available for angiotensin ii, des-phe(8)- and deoxycytidine

Article	Year
Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:6 Topics: Angiotensin I; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Proliferation; Deoxycytidine; Drug Synergism; Epoetin Alfa; Erythroid Precursor Cells; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematinics; Megakaryocytes; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Peptide Fragments; Recombinant Proteins; Stem Cells; Time Factors	2013
Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression. Haematologica, 2018, Volume: 103, Issue:12 Topics: Administration, Oral; Angiotensin I; Animals; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Mice; Myelopoiesis; Peptide Fragments	2018

Article

Year

Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery.

Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:6

Topics: Angiotensin I; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Proliferation; Deoxycytidine; Drug Synergism; Epoetin Alfa; Erythroid Precursor Cells; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematinics; Megakaryocytes; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Peptide Fragments; Recombinant Proteins; Stem Cells; Time Factors

2013

Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression.

Haematologica, 2018, Volume: 103, Issue:12

Topics: Administration, Oral; Angiotensin I; Animals; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Mice; Myelopoiesis; Peptide Fragments

2018